Videos

  Clinical Conversations by Experts View all

Navigating Cancer Care Costs

Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives

ESMO 2024 Quick Takes

2024 Conferences - Clinical Conversations

Featured Videos

36-Month Efficacy of Nadofaragene in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer - Yair Lotan
BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence - Ali Nasrallah
Belzutifan vs Everolimus Trial Data in Advanced RCC Care - Brian Rini
AI-Powered Prostate Cancer Risk Assessment Tool Validated for Low-risk and Active Surveillance - Andre Esteva
SWOG Trial On Standard vs Extended Lymphadenectomy in Muscle Invasive Bladder Cancer - Seth Lerner
NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles
Advancing mHSPC Treatment Options: ARANOTE Trial Analysis - Neal Shore & Fred Saad
Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard
Radiation Therapy Options for Localized Prostate Cancer Compared in Major Trial - Jason Efstathiou
PEACE 3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad
SunRISe-1 Trial Advances Bladder Cancer Treatment with TAR-200 - Michiel Van der Heijden
RAPSON Trial Explores Radium223 and Docetaxel Sequencing in mCRPC - Vincenza Conteduca
Darolutamide Improves Outcomes for mHSPC Patients in ARANOTE Trial - Fred Saad
Financial Distress for GU Cancer Patients: Insights from CDC Survey - Laura Bukavina & Steven Leonard
Cancer-Related Financial Hardship Among Cancer Survivors: Research from the HINTS-SEER Survey - Apoorv Dhir & Rishi Sekar
PARTIQoL Trial: Proton Therapy vs IMRT for Localized Prostate Cancer - Jason Efstathiou
Utilizing the Decipher® mRNA Score for Risk Stratification in mHSPC - David Morris and Ashley Ross
PEACE-3 Trial Results: Radium-223 + Enzalutamide in mCRPC - Bertrand Tombal
UpFrontPSMA Trial: Lutetium-PSMA + Docetaxel in mHSPC - Arun Azad
EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore
ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment - Fred Saad
PEACE-1 Trial Reveals Key Genomic Alterations Linked to Survival in Prostate Cancer Patients - Cédric Pobel
SunRISe-4 Trial Explores TAR-200 and Cetrelimab Combination for Bladder Cancer Treatment - Andrea Necchi
Fecal Microbiota Transplant Boosts Immunotherapy in Metastatic Renal Cell Carcinoma in TACITO-II Trial - Chiara Ciccarese
Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky
PRINCE Trial Highlights Early Detection of Prostate Cancer Progression with PSMA PET-CT - Michael Hofman
COTRIMS Trial Shows High Cure Rates with RPLND in Stage IIA/B Seminoma - Axel Heidenreich
AMBASSADOR Trial: Extended Follow-up on Adjuvant Pembrolizumab in Bladder Cancer - Andrea Apolo
SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment - Oliver Sartor
TiNivo-2 Trial Results in Advanced Renal Cell Carcinoma Treatment - Toni Choueiri
Genetic Profiles in Early vs. Late Stage Urothelial Cancer - Dag Stormoen
Patient Perspectives on Bladder Cancer: Balancing Treatment Options and Shared Decision-Making - Roger Li
Cardiovascular Risks of ARSIs in Prostate Cancer: Meta-Analysis Findings, Journal Club - Rashid Sayyid & Zachary Klaassen
Robotic Mini-PCNL and Ureteroscopy: Advancing Kidney Stone Treatment "Presentation" - Jaime Landman
Phase 3 CLARIFY Trial Investigates 64Cu-SAR-bisPSMA PET for Improved Prostate Cancer Detection - Louise Emmett
CLARIFY Trial: Advancing Prostate Cancer Imaging with 64Cu-SAR-bisPSMA PET - Neal Shore
COURAGE Trial: Vibegron for BPH Patients with Persistent OAB Symptoms - David Staskin
Overcoming Hormone Resistance: ARV-766 in Advanced Prostate Cancer - Daniel Petrylak
Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff
Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy - Irene Casanova-Salas & Joaquin Mateo
Reservations About a Nomenclature Change for Gleason Grade 1 Prostate Cancer "Presentation" - Adam Kibel
Trimodal Therapy in Urothelial vs Non-Urothelial Bladder Cancer - Mario de Angelis
Cell Surface Targets in mCRPC: Expression Landscape and Therapeutic Potential - Michael Haffner
Urologic Oncology Clinical Trials: Size, Scope, and Impact - Kristian Stensland
Oxybutynin-Associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment - Beyond the Abstract
Reducing Prescription Drug Costs: 4 Online Tools for Urology Patients - Benjamin Pockros
FGFR3 Inhibition for Upper Tract Urothelial Cancer: Phase 1b Trial Results - Surena Matin
Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results - Yousef Zakharia
PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi
Post-Prostatectomy Care: Variability in Treatment for Lymph Node Positive Prostate Cancer - Daniel Triner
dMMR and MSI-H in Urothelial Carcinoma: Prevalence and Treatment Implications - Elias Chandran
Meta-Analysis Evaluates Cardiovascular Risks of AR Inhibitors in Prostate Cancer - Omar El-Taji & Ashwin Sachdeva
Functional Renal Imaging and Advances in Kidney Cancer Detection - Shankar Siva
CYCLONE 2 Trial Results: Abemaciclib in Metastatic Castration-Resistant Prostate Cancer - Matthew Smith
Breaking Barriers in Cancer Treatment and Women's Leadership in Oncology - Ulka Vaishampayan
PSCA CAR T-Cell Therapy for Metastatic CRPC: Phase 1 Trial Results - Tanya Dorff
Mental Health and Prostate Cancer in the Veterans Population - Zachary Klaassen
2024 NCCN Guidelines: Simplifying the Management of Very Low-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
Bladder-Sparing Chemoradiation for Localized Bladder Cancer: Addressing the Unmet Need - Brent Rose
SunRISe-5 Trial: Evaluating TAR-200 for Recurrent High-Risk Non-Muscle Invasive Bladder Cancer - Sima Porten
IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer - Stacy Loeb
Machine Learning Model Predicts Overall Survival in Metastatic Prostate Cancer - Ali Sabbagh
Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal
ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC - Edmond Kwan
ARAMIS Trial: PSA Responses with Darolutamide Linked to Minimal Radiographic Progression - Alicia Morgans
Bridging the Gap in Microhematuria Evaluation: A Discussion on the STRATA Trial - Yair Lotan
Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in CHAARTED Trial Subset - Mark Markowski
OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan
Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi
COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection - Phillip Koo
Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial - Fred Saad
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Current Landscape and Future Directions - Matthew Galsky & Neal Shore
CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li
Prostate Cancer Knowledge and Screening Barriers in Northern Tanzania: A Community-Based Study - Blandina Mmbaga & Nicholas Ngowi
Apalutamide for Preventing Bladder Cancer Recurrence: A Proof-of-Principle Trial - Edward Messing
UCHL1: A Potential Biomarker and Therapeutic Target for Neuroendocrine Prostate Cancer - Tanya Stoyanova
Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care Systems - Isla Garraway
Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin
Testosterone Recovery After ADT: Timing, Predictive Factors, and Clinical Implications - Pierre Blanchard
Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence - Daniel Spratt
COBRA Trial Shows Promise for 64Cu-SAR-bisPSMA PET in Biochemical Recurrence - Neal Shore
Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie
Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis
Risk Classification for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Using Machine Learning Based Predictions - Beyond the Abstract
The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo
Balancing Bladder Preservation with Effective Treatment in Cancer Care - Petros Grivas
Treatment Options for Advanced Urothelial Cancer Post-EV-302 - Shilpa Gupta & Karima Oualla
Integrating Nadofaragene Firadenovec into Clinical Practice for Non-Muscle Invasive Bladder Cancer Treatment - Ashish Kamat
BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson
VA BRAVO 2 Study: Blue Light Cystoscopy Improves Outcomes in NMIBC Patients in Equal Access Setting - Stephen B Williams
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer AUA/SUO Guideline - 2024 Amendment - Jeffrey Holzbeierlein
Navigating the Shift to Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer: Key Considerations for Clinicians - Cora Sternberg
Darolutamide Outcomes in European Patients with Metastatic Hormone-Sensitive Prostate Cancer from the ARASENS Trial - Bertrand Tombal
Preclinical Study Evaluates Enfortumab Vedotin and Sacituzumab Govitecan with Radiation for Bladder Cancer - Kent Mouw
Local Therapy in mHSPC: Who Does Really Benefit? - Alberto Bossi
Genomic Tumor Correlates of Response to Trimodal Therapy for Muscle-Invasive Bladder Cancer - Sophia Kamran
The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore
The Future State of Race & Ethnicity in Urology: Urology Workforce Projection from 2021-2061 - Efe Chantal Ghanney Simons & Ashley Appleton
A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy - Beyond the Abstract
Novel 18-Gene Urine Test Improves Detection of Clinically Significant Prostate Cancer - Jeffrey Tosoian
Patient-Driven Outcomes in the CISTO Trial for High-Grade Non-Muscle Invasive Bladder Cancer - Angela Smith & John Gore
Non-Metastatic Castration-Resistant Prostate Cancer in the Era of PSMA PET Imaging - Aaron Berger
Maximizing Survival in Metastatic Hormone-Sensitive Prostate Cancer: The Role of Triplet Therapy - Kelvin Moses
Teamwork and Trust: Keys to Seamless Prostate Cancer Care Across Specialties - Paul Eber & Brad Somer
Best Practices for Successfully Implementing Triplet Therapy in mHSPC - Christopher Pieczonka
Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases - Karim Fizazi
Advancements in Cutting-Edge SABR Therapy for Oligometastatic Kidney Cancer - Shankar Siva
Patient Selection for Radioligand Therapy: Case Study Discussion - Amir Iravani & Evan Yu
Implementing Nadofaragene Firadenovec Treatment in NMIBC - Mark Tyson, Aimee Boden, & Meghann Davis
Topical Estrogen Therapy in Preventing Recurrent UTIs in Women - Rachael Sussman, Charlotte Houston with Ruchika Talwar
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Sequential Gemcitabine and Docetaxel Shows Promise for Intermediate-Risk NMIBC - Vignesh Packiam
Age Alone Should Not Preclude BCG Therapy in NMIBC - Ashish Kamat
Novel Computational Approach Identifies NME2-MYC Axis as Biomarker and Therapeutic Target in Enzalutamide-Resistant CRPC - Antonina Mitrofanova
Combining Pembrolizumab and BCG Immunotherapies: The KEYNOTE-676 Trial in High-Risk NMIBC - Neal Shore
Advancing Personalized Medicine: Examining Trop2 as a Biomarker to Stratify Prostate Cancer Patient Risk - Tanya Stoyanova
COMBAT Trial Yields Promising Results for Bipolar Androgen Therapy Plus Nivolumab in Metastatic Castration-Resistant Prostate Cancer - Mark Markowski & Emmanuel Antonarakis
The Use of Imaging in Staging Localized Prostate Cancer: A Case Study on High-Risk Localized Prostate Cancer - Zachary Klaassen
Exploring New Approvals in Non-Muscle Invasive Bladder Cancer Treatments for BCG Unresponsive Patients - Mark Tyson
PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mark Tyson
Establishing Nadofaragene Firadenovec in a Large Urology Practice - Daniel Canter
Real-World Use of Nadofaragene Firadenovec - Siamak Daneshmand
Patient Selection for PSMA Radioligand Therapy - Ephraim Parent
Access to Cutting-Edge Therapies and Clinical Trials in the VA- Matthew Rettig
Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor
Radioligand Therapy's Role in Treating mCRPC - Oliver Sartor
Highlights: UCLA/UCSF Inaugural PSMA PET and RLT Conference - Jeremie Calais
Distinct Mesenchymal Cell States Mediate Prostate Cancer Progression - Massimo Loda
Access and Utilization of Healthcare by Adults with Spina Bifida - Lindsay Hampson & Alejandro Lopez
Comparing Cost-Effectiveness of Surgery, Radiation, and Chemo for Seminoma - Daniel Joyce
Testicular Cancer Survivors Find Community and Healing Through Foundation and Patient Summit - Connor O'Leary & Charles Freeman McCluskey
Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
Chinese Subgroup Analysis Reveals Both Similar and Distinct Responses to Novel Darolutamide Combination Therapy - Yao Zhu
Socioeconomic Disparities Drive Alarming Racial Gaps in Kidney Cancer Patient Survival Rates - Nirmish Singla
Novel Research Illuminates How CXCR7 Protein Interactions Promote Growth of Neuroendocrine Prostate Cancer - Jindan Yu
How Chemotherapy Drives Metastasis By Causing Tumor Cells to Become Significantly More Mobile - Sarah Amend
Deciphering Prostate Cancer: How Genomic Biomarkers are Shaping Treatment Decisions - Paul Nguyen
Exploring the Multifaceted Role of a Medical Oncologist in Advanced Prostate Cancer Care and Management - Alicia Morgans
Novel STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly
Genetic Testing Reveals Treatment Opportunity and Disparity in Advanced Prostate Cancer - Colin Pritchard
INDICATE Trial Seeks to Clarify Role of PET Scans in Prostate Cancer Recurrence - Neha Vapiwala
The Complex Web of SPOP Mutations and STING1 Signaling in Prostate Cancer - Patrick Pilié
Innovative Prostate Cancer Therapy Insights Unveiled in ESMO 2023 Meeting - Alan Bryce
The LITESPARK-013 Trial and Belzutifan's Optimal Dose for Treating Metastatic Renal Cell Carcinoma - Neeraj Agarwal
Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming
Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi
Correlation and Validation of Gene Expression Classifiers in Prostate Cancer: A Large-Scale Study - Daniel Spratt
PSMAfore Study Unveils Game-Changing Results for Prostate Cancer Treatment - Oliver Sartor
Prostate Cancer Drug Costs: A Complex Landscape of Out-of-Pocket Expenses - Benjamin Pockros
Innovation in Oncology Drug Pricing: A Comparative Study of Savings Potential - Ruchika Talwar & Brian Cortese
Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross
A Breakthrough in Urothelial Cancer Treatment: Enfortumab Vedotin Combination Therapy - Expert Insights and Impressive Response Rates - Jonathan E. Rosenberg
The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mCRPC - Susan Halabi
Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Jason Efstathiou & Alexandre Zlotta
Choosing JELMYTO®: A Patient's Journey Through Less Invasive Upper Tract Urothelial Carcinoma Treatment - Tom Murphy
Beyond BRCA-1 and 2: The Impact of the TALAPRO-2 Study on Prostate Cancer Care - Cora Sternberg
Exploring Erdafitinib: A Breakthrough in Non-Muscle Invasive Bladder Cancer Treatment - Siamak Daneshmand
Personal Passion Fuels Progress: Unraveling Prostate Cancer Aggressiveness in Black Men - Leanne Woods-Burnham
Gene Therapy for NMIBC: A New Era of Treatment - Colin Dinney
Enhancing Patient-Centered Communication in Small Renal Mass Management - Kathryn Hacker Gessner
Journal of Urology Open Plus - Revolutionizing Access and Innovation in Urology Research - John W. Davis
Improving Primary Prostate Cancer Diagnosis Through Risk Stratified Screening: a European Perspective - Sigrid Carlsson
Combining Belzutifan Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma, Exploring Novel Therapy Options - Toni Choueiri
Risk Assessment in Localized Prostate Cancer - Insights from Real-World Data and SEER Registry - Jim Hu
Insights into the AUA Guidelines for Upper Tract Urothelial Carcinoma: Standardizing Diagnosis and Treatment for Better Patient Outcomes - Jonathan A. Coleman
ProtecT Trial Reveals New Insights for Prostate Cancer Treatment: Implications for Low-Risk vs. High-Risk Patients - David Penson
Assessing the Effectiveness of N-803 for BCG Unresponsive Bladder Cancer: Promising Complete Remission Rates and Improved Long-Term Response - Patrick Soon-Shiong
PSMA-Targeted Radioligand Therapy and Liquid Biopsy Characterizing PSMA Expression in Men with Metastatic Castration-Resistant Prostate Cancer - Andrew Armstrong
Targeting the HLA-E/NKG2A Axis to Overcome BCG Resistance in NMIBC, BCAN Translational Clinical Trial Award - Amir Horowitz
Safety and Disease Related Outcomes of mCRPC Patients Who Were Treated with Radium-223 Then 177Lu-PSMA (RALU) - Neal Shore
Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad
The Role of Awareness and Support in Elevating Women in Science - Kristen Scarpato & Svetlana Avulova
Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis
Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi
Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard
A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore
CAR T and Cellular-Based Therapies - Vivek Narayan
The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore
Timing of Radical Cystectomy in BCG Unresponsive Disease - Patrick Hensley
Women in Urologic Oncology - Anne K. Schuckman
Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans
Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff
Clinical Trial Endpoints in the Adjuvant Setting for Renal Cell Carcinoma and Urothelial Cancer - Andrea Apolo and Pavlos Msaouel
The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff
Bladder Cancer Highlights - Stephen Williams
APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu
Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans
EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer – Jonathan E. Rosenberg
A Urologist's Perspective on the PROpel Trial, Olaparib and Abiraterone versus Abiraterone Alone, in the First-Line Metastatic Castration-Resistant Prostate Cancer Setting - Neal Shore
An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt Attard
Smarter Screening In Prostate Cancer - Sigrid Carlsson
CheckMate 214: A Deep Dive into Ipilimumab and Nivolumab for Advanced Renal Cell Carcinoma - David Cella
Evaluating the Impact of Variant Histology Pathologic Diagnosis on Survival Outcomes in Patients with Upper Tract Urothelial Carcinoma - Wesley Yip
Upper Tract Urothelial Carcinoma Highlights - Nima Almassi
A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore
Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal
Darolutamide Approved for Patients with mHSPC - Charles Ryan
The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta
First Standardized Framework Measuring PSMA PET/CT Response in Metastatic Castration‑Resistant Prostate Cancer - Wolfgang Fendler and Andrei Gafita
The 6th Global Summit On Precision Diagnosis and Treatment Of Prostate Cancer - Faina Shtern, The AdMe Tech Foundation
The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy - Stephen Freedland
Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101 in the OLYMPUS Trial - John Gore
Management Trends & Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma, the USC Experience - Anirban Mitra
Comparative Effectiveness of Neoadjuvant Chemotherapy In Bladder And Upper Urinary Tract Urothelial Carcinoma - Jeffrey Holzbeierlein
Preventing Recurrence of Urothelial Carcinoma in Patients with Upper Tract Carcinoma - Aditya Bagrodia
Convatec GentleCath™ Glide No-Touch Catheters - Diane Newman
Uncoated Catheters - Diane Newman
Closed Catheters Systems - Diane Newman
Treatment Sequencing with Radium-223 in Symptomatic Disease - Fred Saad
Depression, Bone Health and Exercise in Prostate Cancer - Fred Saad, Tomasz Beer & Charles Ryan
Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin
Self Intermittent Catheters Types - Diane Newman
Surveillance Guidelines for Low-Grade Ta NMIBC Often Not Followed - Stephen Williams
A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore
Mental Health and Impact on Patients with GU Malignancies - Zachary Klaassen
The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore
PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad
Identifying Unmet Needs in the Patient Journey in Prostate Cancer - Alicia Morgans
Future Perspectives in Prostate Imaging in Developing Countries - Ronaldo Hueb Baroni
Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz
Microbiome Research in Bladder Cancer - Laura Bukavina
Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas
The Management of High-Risk Localized Disease and Double Therapy in the mCRPC Setting - Andrey Soares
Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp
Evidence Supporting the Use of Urinary Catheters for Intermittent Catheterization - Diane Newman
Lessons Learned in the STAMPEDE Trial - Nicholas James
Treatment Delay Experiences Among Black and White Men with Prostate Cancer - Bhav Jain & Christopher Dee
Mechanistic Pathway Through Which Saphenous Nerve Stimulation Can Modulate Bladder Function - Paul Yoo
Developing A Novel Neuromodulation Therapy for Treating Overactive Bladder - Anne Agur
Radiotherapy Guided by PSMA PET Molecular Imaging - Juan Galvis Serrano
Preparing for Treatment with 177Lu-PSMA-617 - Kendra Harris
Administering Pluvicto™ - A Patient Shares His Treatment Experience of 177Lu-PSMA-617 - Kendra Harris and Phillip Koo
Higher Rates of Metastatic Disease on PSMA PET for Biochemical Recurrence Risk Groups, Journal Club - Christopher Wallis & Zachary Klaassen
The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra
Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher
The Role of Bladder-Sparing Trimodality Therapy - Sophia Kamran
Biological Pathways in Urothelial Carcinoma - Carissa Chu
Long-Term Safety and Durability to Non-Surgical Treatment Instillation of UGN-101, Mitomycin-Containing Reverse Thermal Gel for Low-Grade Upper Tract Urothelial Carcinoma, Journal Club - Zachary Klaassen and Christopher Wallis
Treating Women with Bladder Cancer and a Community Approach to Navigating a Diagnosis - Jeannie Hoffman-Censits & Elizabeth Guancial
The Upcoming 2022 European International Kidney Cancer Symposium - Samra Turajlic
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients with High-Grade Upper Tract Urothelial Carcinoma - Wesley Yip
Radiation Safety and the Integration of Pluvicto™ (177Lu-PSMA-617) in Treatment of mCRPC- Kendra Harris
Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne
Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris
The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen
Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg
Symptoms Related to Bone Metastasis in Men Receiving Lutetium-177 PSMA-617 for Prostate Cancer - Brian Gonzalez
Pluvicto The First Targeted Radioligand Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer FDA Approved - Charles Ryan and Alicia Morgans
Molecular Biomarkers in Upper-Tract Urothelial Carcinoma - Janet Kukreja
Associations of Adverse Pathology With 20 Year Risk of Distant Metastasis and Prostate Cancer Specific Mortality - Michael Brooks
The Effect of Durvalumab and Olaparib on Prolong Progression-Free Survival As First-Line Therapy in Platinum-Ineligible Patients With Unresectable Urothelial Carcinoma - The BAYOU Study – Jonathan Rosenberg
Treatment and Survival Differences in Patients With Urothelial Vs. Nonurothelial Bladder & Upper Tract Carcinomas - Jeanny Aragon-Ching
Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy - Eric Klein
The Next Wave of Novel Radiopharmaceuticals - Shahneen Sandhu
Appropriate Use Criteria for PSMA PET Imaging - Hossein Jadvar
KEYNOTE-564 30-Month Follow-Up of Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma - Toni Choueiri
DS8201-a-U105 Trial of Trastuzumab Deruxtecan With Nivolumab in Patients With Urothelial Carcinoma – Matt Galsky
Validation of Performance of the Decipher® Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi
PSMA PET/CT Imaging Indications in Prostate Cancer - Neal Shore & Oliver Sartor
Research in Biomarkers for Bladder Cancer - The BCAN Young Investigator Awards - Benjamin Miron
Quality of Life for Patients Undergoing Radical Cystectomy - Bernard Bochner
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
Perioperative Optimization for Patients Undergoing Radical Cystectomy – Sarah Psutka
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
Financial Toxicity Among Patients with Bladder Cancer - Deborah Kaye
From the Stage to the Clinic and Back: Medicine and Burnout - Stuart H. Bloom
Bladder Cancer: A Practical Guide - Ashish Kamat & Peter Black
NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and Chris Wallis
Demonstrated Underuse of Blue Light Cystoscopy for Bladder Cancer in the United States - Patrick Lewicki
Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan
NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff
A Real-World Analysis of Pain Efficacy of Radium-223 Treatment Among Patients With Metastatic Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases – the REASSURE Trial – Celestia Higano
Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor
PSMA Imaging - Is Conventional Imaging Obsolete - Steven Rowe
Management of Small Local Recurrence Low-grade Bladder Tumors with Negative Cytology - Marek Babjuk, Morgan Roupret & Wassim Kassouf
Urogynecology Controversies: Female Pelvic Medicine and Reconstructive Surgery - Briana Walton
Treatment-Related Regret Among Men With Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen
Theranostics - Taking Over Prostate Cancer Care? - Phillip H. Kuo
Understanding Physiological PSMA Biodistribution - Jeremie Calais
Women in Science and The Prostate Cancer Foundation - Amina Zoubeidi
Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer - Heather Payne
The World Bladder Cancer Patient Coalition Launches Bladder Cancer Patient Survey
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack
Single-Use Disposable Cystoscopy - Roger Dmochowski, David Chaikin, & Vijay Goli
Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors CABA-GCT - Giulia Baciarello
Financial Toxicity in Bladder Cancer—A Mixed Methods Study of Two Diverse Patient Populations - Sumeet Bhanvadia
Real-World Data in Second-Line Treatment Progressing mCRPC – Oliver Sartor
Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio
Antegrade Endoscopic Upper Tract Approaches - Ryan Hsi
Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke
Upper Tract Urothelial Carcinoma - Clinical Case Management in High-Risk Disease - Sima Porten
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz
Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore
STAMPEDE Analysis of Abiraterone With or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone In High-Risk Non-Metastatic Prostate Cancer Patients– Gerhardt Attard
A Novel Sublingual Vaccine for Prevention of Recurrent Urinary Tract Infections in Women - J. Curtis Nickel
Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi
Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi
The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder - Michael A. Weber
Choice of Urinary Diversion in Patients Undergoing Radical Cystectomy - Peter Black, Jens Bedke, and Hugh Mostafid
Impact of Age on Castration Rates from The HERO Study – Michael Cookson
Risk Stratification of Upper Tract Urothelial Carcinoma - Doug Scherr
Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis - Beyond the Abstract
The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher® Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra
When to Add ADT to Early or Late Salvage Radiation - Dan Spratt
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt
Radium-223 Treatment for Metastatic Prostate Cancer - Ila Sethi
Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo
The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff
Health-Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma in the CLEAR Trial – Bradley McGregor
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
The OAB Clinical Care Pathway Mobile APP - Stephen Kraus
Management and Challenges of Low Grade Upper Tract Urothelial Carcinoma - Surena Matin
The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer - BCAN New Discoveries Young Investigator Award - Eugene J. Pietzak
Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu
PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu
The Management of Primary Carcinoma of The Urethra - Reza Mehrazin
18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen
Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone
Defining the Standard of Therapy for First-Line mHSPC - Lisa Horvath
Sexual Function in Women Undergoing Radical Cystectomy, BCAN New Discoveries Young Investigator Award for Patient-Centered Research - Svetlana Avulova
How I Use Jelmyto™ - Karim Chamie
177LuPSMA-617 - A New Standard of Care in the Treatment of mCRPC Based on The Phase III VISION Trial Results - Michael Morris
A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher Wallis & Zachary Klaassen
PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval - Michael Morris
Results From the IGCCCG Update Consortium in Metastatic Seminoma And Nonseminomatous Germ Cell Tumors – Silke Gillessen
Upper Tract Urothelial Carcinoma - Clinical Case Management – Jonathan Coleman
Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun
The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker
Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal
Survivorship in Testicular Cancer - Mary Dunn
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal
Pembrolizumab in the Real-World Setting for Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG - Arjun Balar
Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak
Facing Pelvic Pain - Elise De
Cabazitaxel is Active in Men with mCRPC with DDR Alterations - Karim Fizazi and Mihaela Aldea
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
The Role and Timing of Urodynamics and Certificate in Urodynamics Virtual Course - Hashim Hashim
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt
Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor
Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal
Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner
Surgical Simulator for Laparoscopic Partial Nephrectomy for Renal Cell Carcinoma - Gonzalo Vitagliano
NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff
The Accidental Journey of Shepherding PSMA PET Imaging in Prostate Cancer to the Clinic in the United States - Thomas Hope
Clinical Implications of the Study Findings from the Radiotherapy Adjuvant Versus Early Salvage ((TROG 08.03/ANZUP RAVES) Trial - Andrew Kneebone and Declan Murphy
Operationalizing Genomic Testing for Clinical Practice In Prostate Cancer - Jason Hafron
The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans
Nadofaragene Firadenovec for BCG Unresponsive NMIBC - Girish Kulkarni
68Ga-PSMA-11 Joins FDA-Approved Tools for Management of Prostate Cancer - Thomas Hope
Racial Differences in Genomic Profiling in Prostate Cancer - Brandon Mahal
Overall Survival Data from the Global, Phase 3 ARAMIS Trial in Men with Non Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi
Changing the Standard of Care in Prostate Cancer with Advances in Nuclear Medicine, PET and Theranostics Symposium - Rob Flavell
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III
Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) - Ben Tran
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener 
Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans
The Role of FoundationOne® Liquid CDx in mCRPC - Oliver Sartor
The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo
DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao
Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney
PSMA-directed Therapy - Scott Tagawa and Michael Morris
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu
Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma - Alison Birtle & Surena Matin
A Discussion on Implementing the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines - Sam Chang
Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer - Sia Daneshmand & Trinity Bivalacqua
Improving and Optimizing Transurethral Resection of Bladder Tumor (TURBT) Outcomes - Hugh Mostafid
In His Own Voice: His 15-Year Journey with Advanced Prostate Cancer - Steve Poggi
A Debate on The Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patients: Pembrolizumab Vs. Nadofaragene Firadenovec - Arjun Balar & Peter Black
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore
Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida
Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen
IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Christopher Sweeney
Implications of the Bacillus Calmette-Guérin (BCG) Shortage - Joshua Meeks
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor
In Pursuit of Patient-Centered Care - Karen Knudsen
Making Your Treatment Decision - Prostate Cancer Patient Interview with Andy Schwartz
Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith
NCCN Localized Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer
NCCN Metastatic Castration-Resistant Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer and Alicia Morgans
Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore
The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran
Moving the Field Forward, Upper Tract Urothelial Carcinoma, The POUT Study - Alison Birtle
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz
CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi
A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris
First-line Therapy Options for Metastatic Renal Cell Carcinoma - Tian Zhang
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran
Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients – Oliver Sartor
Genetic Counseling in Prostate Cancer - Brittany Szymaniak
Darolutamide Treated Patients Maintained Quality of Life in ARAMIS Trial - Fred Saad
Clinical Trials: Another Treatment Option for Patients - Tom Farrington
Radium-223 in Clinical Practice - Phillip J. Koo
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans
Challenges in the Diagnosis and Treatment of UTUC - Peter Black
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
Immunotherapy Across Genitourinary Malignancies - James Gulley
Optimizing ADT in Prostate Cancer Patients - Tom Keane
Blue Light Cystoscopy for Diagnosis of Bladder Cancer - A Journal Club Review by Badrinath Konety
High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks
CARMENA: Practice Changing Strategies for Kidney Cancer
Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
Nocturia in the Aging Patient, Assessment and Treatment- Susann Varano
Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng
The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor
Update on Bladder Cancer, Current Trials and Treatments - Bishoy Faltas
Dedication to Multidisciplinary Management of GU Oncology - Alex Kutikov
Clinical Implications of the Abi Race Study: Interview with Dan George
Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo
Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons
Geriatric Assessment of Men with Prostate Cancer - Alicia Morgans
New Concepts in ADT- Thomas Keane
Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas
nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.
Defining Bladder Health - Ariana Smith
A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - Neal Shore
Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin

Genomic Classifier in Prostate Cancer: High-Risk

Epidemiology Applied to Focal Therapy in Prostate Cancer: Where do we Stand? - Kae Jack Tay
The Future of Prostate Cancer Risk Stratification and Treatment Planning - Eric Kim
The Future of Prostate Cancer Diagnosis: Combining Non-Invasive Tests for Personalized Care - Eric Kim
Investigating the Relationship Between MRI Findings, Genomic Markers, and Gleason Score - Eric Kim
Decipher® Scores and PSMA PET Imaging: A Correlative Study in High-Risk Prostate Cancer - Amar Kishan
Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard
Adjuvant Treatment for Men with Prostate Cancer with High Risk of Metastasis, the ERADICATE Study - Ashley Ross
Decipher® Biopsy and Decipher® for Prostatectomy in Clinical Practice- Ashley Ross
The Benefit of ADT Treatment Intensification With Radiotherapy in Localized Prostate Cancer – Dan Spratt and Amar Kishan
The Conundrum of Systemic Salvage Therapy at the Time of Salvage Radiation Therapy - Brandon Mahal
The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra
The Impact of Decipher® Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher® Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt
Prognostic Utility of Decipher® Prostate Genomic Classifier in the SAKK 09/10 Phase III Trial - Alan Dal Pra
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt

High-Risk Non-Muscle Invasive Bladder Cancer

Advanced Bladder Cancer

Addressing Cognitive Decline in Bladder Cancer Patients Through Prehab and Rehab - Sarah Psutka
Bridging Evidence to Practice: Bladder Cancer Therapy Guidelines and Global Implementation - Andrea Apolo
SWOG Trial On Standard vs Extended Lymphadenectomy in Muscle Invasive Bladder Cancer - Seth Lerner
EV-302 Trial Analysis Evaluating Nectin-4 in Urothelial Cancer - Thomas Powles
NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles
Variant Histology Bladder Cancer Challenges and Future Directions - Syed Hussain
Bladder Cancer Research Explores Fecal Transplants and Nutritional Strategies - Laura Bukavina
Highlights in Non-Prostate GU Oncology from ESMO 2024 - Ignacio Duran
Enfortumab Vedotin and Stereotactic Radiation Tested Before Surgery in Muscle-Invasive Bladder Cancer in STAR-EV Trial - Tian Zhang
Event-Free Survival as Surrogate Endpoint in Muscle Invasive Bladder Cancer Research - Cora Sternberg
Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trials - Maria De Santis
SunRISe-4 Trial Explores TAR-200 and Cetrelimab Combination for Bladder Cancer Treatment - Andrea Necchi
Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky
AMBASSADOR Trial: Extended Follow-up on Adjuvant Pembrolizumab in Bladder Cancer - Andrea Apolo
Trimodal Therapy in Urothelial vs Non-Urothelial Bladder Cancer - Mario de Angelis
The Best of ASCO 2024 in Advanced Bladder Cancer - Shilpa Gupta
Small Cell Neuroendocrine Carcinoma of Urinary Tract: Relapse Factors & Treatment - Omar Alhalabi
dMMR and MSI-H in Urothelial Carcinoma: Prevalence and Treatment Implications - Elias Chandran
Bladder-Sparing Chemoradiation for Localized Bladder Cancer: Addressing the Unmet Need - Brent Rose
EV-302 Subgroup Analysis: Improved Outcomes for Cisplatin-Ineligible Advanced Urothelial Cancer Patients - Michiel Van der Heijden
SunRISe-2 Trial: TAR-200 and Cetrelimab vs. Chemoradiotherapy for Muscle-Invasive Bladder Cancer - Stephen Williams
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Current Landscape and Future Directions - Matthew Galsky & Neal Shore
Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie
AUA 2024 Urothelial Carcinoma Highlights - Woodson Smelser
Pembrolizumab + Chemoradiation vs. Trimodality Therapy for Muscle-Invasive Bladder Cancer: The KEYNOTE-992 Trial - Neal Shore
Immunotherapy Advancements in Bladder Cancer: Clinical Trials, Early Intervention, and Toxicity Management - Matt Galsky & Neal Shore
Balancing Bladder Preservation with Effective Treatment in Cancer Care - Petros Grivas
Treatment Options for Advanced Urothelial Cancer Post-EV-302 - Shilpa Gupta & Karima Oualla
Stool Microbiome Signature Predicts Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer - Filippo Pederzoli & Massimo Alfano
EV-302 Subgroup Analyses: Enfortumab Vedotin + Pembrolizumab Effective Across Patient Subsets in Metastatic Urothelial Cancer - Jonathan Rosenberg
Navigating the Shift to Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer: Key Considerations for Clinicians - Cora Sternberg
Preclinical Study Evaluates Enfortumab Vedotin and Sacituzumab Govitecan with Radiation for Bladder Cancer - Kent Mouw
Genomic Tumor Correlates of Response to Trimodal Therapy for Muscle-Invasive Bladder Cancer - Sophia Kamran
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma - Arlene Siefker-Radtke
EV-302: Enfortumab Vedotin + Pembrolizumab Outperforms Chemo in Untreated Advanced Urothelial Cancer - Michiel Simon Van der Heijden
Adjuvant Pembrolizumab in Urothelial Carcinoma: AMBASSADOR Study Findings - Andrea Apolo
Outcomes of Enfortumab Vedotin After Platinum and Avelumab in Bladder Cancer - Amanda Nizam
Combination Maintenance Therapy for Advanced Bladder Cancer Explored in MAIN-CAV Study - Shilpa Gupta
Utilization of Neoadjuvant Chemo Before Cystectomy - Hiten Patel
International Panel Defines Endpoints and Control Arms for Trials in Locally Advanced and Metastatic Bladder Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Multi-Disciplinary Panel Defines Clinical Trial Framework for Muscle-Invasive Bladder Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Gemcitabine, Cisplatin and Immunotherapy: A Promising Mix for Advanced Bladder Cancer - Guru Sonpavde & Matthew Galsky
Novel Antibody-Drug Conjugate Combination Yields High Response in Advanced Bladder Cancer - Guru Sonpavde & Bradley McGregor
For Bladder Cancer Patients, New Hope From Immunotherapy Innovations from ESMO 2023 - Petros Grivas
The EV-302 Study and the Implications for Metastatic Bladder Cancer Care - Cora Sternberg
EV-103 Study Update: Impressive Four-Year Data on Enfortumab Vedotin and Pembrolizumab Combination in Urothelial Cancer - Shilpa Gupta
Outcomes with Immune Checkpoint Inhibitors in Patients with MTAP Alterations in Advanced Urothelial Carcinoma - Rafee Talukder
A Breakthrough in Urothelial Cancer Treatment: Enfortumab Vedotin Combination Therapy - Expert Insights and Impressive Response Rates - Jonathan E. Rosenberg
Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Jason Efstathiou & Alexandre Zlotta
New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with Second-Line Immune Checkpoint Inhibitors - Beyond the Abstract
The San Raffaele Urologic Oncology Retreat: Examples of ECOG-ACRIN Research Initiatives - Petros Grivas
The TAR-200 Device in Muscle-Invasive Bladder Cancer: Safety, Efficacy, and Future Prospects - Mark D. Tyson, II
Addressing Challenges in Bladder Cancer Surgery: Enhancing Patient Outcomes and Preparing for Recovery - Sarah Psutka
Full Data Analysis of the Biology and Performance of Pre- and Post-Pembrolizumab VI-RADS for Predicting Pathological Response in MIBC: Insights from a Comprehensive Clinical Trials Pipeline - Andrea Necchi
Pros and Cons of Organ-Sparing Cystectomy in Bladder Cancer Patients: Balancing Oncologic and Functional Outcomes - Param Mariappan & Maria Carmen Mir
Long-Term Results of the IMvigor130 Study: Atezolizumab with or without Chemotherapy in Metastatic Urothelial Cancer – Matthew Galsky
Neoadjuvant Chemo-Immunotherapy Affect on Downstaging in Cisplatin-Eligible and Ineligible MIBC Patients Prior to Definitive Surgery, HCRN GU14-188: Phase Ib/II Study - Jason Brown
Gemcitabine, Cisplatin, and Nivolumab with Selective Bladder Sparing in MIBC: Co-Primary Endpoint Analysis of HCRN GU 16-256 Phase II Trial - Matthew Galsky
Exploring Genetic Biomarkers of Response to Enfortumab Vedotin in Advanced Urothelial Carcinoma: Analysis of UNITE Dataset - Tanya Jindal & Vadim Koshkin
Assessing the Impact of Enfortumab Vedotin and Pembrolizumab on QoL and Symptom Management in Urothelial Carcinoma: EV-103 Cohort K Study Results - Matthew Milowsky
The Phase 1B NABUCCO Trial: The Use of Either High or Low-Dose Preoperative Ipilimumab plus Nivolumab in Patients with Stage III Urothelial Cancer – Michiel Van Der Heijden
Extended Follow-Up Results of the CheckMate 274 Trial: Adjuvant Nivolumab for Resected Muscle-Invasive Urothelial Carcinoma - Matthew Galsky
Long-Term Follow-up from the JAVELIN Bladder 100 Trial - Srikala Sridhar
The Association Between FGFR3 Alterations and Response to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma - Gopa Iyer
The Use of Biomarkers in the Adjuvant Setting to Understand the Effect of Nivolumab in the Checkmate 274 Study - Andrea Necchi
Results from the Phase 1b/2 FIDES-02 Study: Derazantinib for Metastatic Bladder Cancer with Activating FGFR1/2/3 Genetic Aberrations - Andrea Necchi
Extended Follow-Up Results CheckMate 274 Trial and Results of Pembrolizumab Monotherapy in BCG-Unresponsive HR NMIBC: Findings from Cohort B of the KEYNOTE-057 Trial - Michiel Van der Heijden
TROPHY-U-01 Cohort 3 Primary Analysis Sacituzumab Govitecan in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cancer That Progressed after Platinum-Based Therapy - Petros Grivas
The Future of Immune Checkpoint Inhibitors in the First-Line Treatment of Metastatic Urothelial Carcinoma - Andrea Apolo
The Role of Avelumab Switch Maintenance Immunotherapy in the Front-Line Space of Patients with Advanced Urothelial Cancer - Srikala Sridhar
From Dismal to Promising: Discoveries Transforming Treatment Options for Advanced Urothelial Carcinoma - Shilpa Gupta
Results of Cohort K of the EV-103 Trial EV Monotherapy or in Combination With Pembro in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer - Guru Sonpavde
Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma - Jonathan Rosenberg
EV-201 Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer – Jonathan E. Rosenberg
Molecular Subtyping and Neoadjuvant Chemotherapy in Bladder Cancer - Christopher Wallis & Zachary Klaassen
Pembrolizumab Alone or Combined With Chemotherapy vs Chemotherapy As First-Line Therapy for Advanced Urothelial Carcinoma in the KEYNOTE-361 Trial Journal Club – Christopher Wallis & Zachary Klaassen
CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta
ATLANTIS Trial Explores Precision Medicine in Urothelial Carcinoma - Robert Jones
Overall Response Rate After Immune-Checkpoint Inhibitor Initiation and Post-ICI PFS in Patients With Advanced Urothelial Carcinoma - Dimitrios Makrakis
Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas
Navigating the Complex Landscape of Adjuvant Trials in Urothelial Carcinoma - Robert Dreicer
The Role of ctDNA in Metastatic Urothelial Cancer - Alexander Wyatt
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective - Scott Tagawa
Final Analysis of the ATLANTIS Rucaparib Arm - Simon Crabb
Practice Changing Publications in Urothelial Carcinoma - Deborah Kaye
Treatment Strategies in Advanced Urothelial Carcinoma - Stephen Boorjian
The Future of Adjuvant and Neoadjuvant Therapy for Patients with Muscle-Invasive Bladder Cancer - Tracy Rose
The Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab in the Treatment of Cisplatin-Ineligible Patients in Advanced Urothelial Carcinoma (LEAP-011) - Yohann Loriot
Highlights In Urothelial Carcinoma at GU ASCO 2022 - Guru Sonpavde
Sacituzumab Govitecan in Combination with Pembrolizumab in Metastatic Urothelial Cancer - Petros Grivas
Clinical Outcomes With Anti-PD(L)1 Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma – Dimitrios Makrakis
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
Biomarkers and Next Generation Sequencing in Advanced Bladder Cancer - Noah Hahn
Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew Galsky
Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo
Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma, Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors: TROPHY-U-01 Journal Club – Christopher Wallis & Zachary Klaassen
Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt
Durability and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in the EV-103 Study in Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma – Terence W. Friedlander
Beyond Clinical Trials: Real-World Success with Trimodality Therapy in Bladder Cancer - Sean Sachdev & Praneet Polineni
Updated Results from EV-201 Cohort 2 - Enfortumab Vedotin Is A Potential Non-Platinum Option for Cisplatin-Ineligible Patients Following Anti-PD-1/L1 Treatment - Bradley McGregor
Advances in the Treatment of Metastatic Urothelial Cancer - Matthew Galsky
Breaking Down the TROPHY-U-01 Trial: How Sacituzumab Govitecan Earned FDA Approval for Advanced Bladder Cancer - Neeraj Agarwal & Petros Grivas
Intersection of Biology and Clinical Characteristics Towards Personalized Sequential Treatments for MIBC - Andrea Necchi and Ewan Gibb
The Role of Imaging in Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer: A Case Study of PURE-01 - Andrea Necchi & Laura Marandino
TROPHY-U-01 Results Lead to Accelerated Approval of Sacituzumab Govitecan (Trodelvy) for Pretreated Metastatic Urothelial Carcinoma - Scott Tagawa
Chemoradiation in Urothelial Carcinoma: The Herculean Effort Behind the SWOG 1806 Trial - Petros Grivas
Variant Histologies of Bladder Cancer - Petros Grivas
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal
Voluntary Withdrawal In The US of Durvalumab and of Atezolizumab in Metastatic Urothelial Carcinoma - Petros Grivas
Operationalizing the Use of Avelumab in Clinical Practice, The Phase III JAVELIN Bladder 100 Trial - Brenda Martone
Characterization of The Genomic Landscape of Post-Neoadjuvant Chemotherapy in MIBC Patients- Andrew Lenis
Metastatic and Muscle-Invasive Bladder Cancer European Association of Urology (EAU) Guidelines - J. Alfred Witjes
Molecular Changes Associated with Treatment Response in Muscle-Invasive Bladder Cancer Patients Treated with Cisplatin-Based Chemotherapy - Lars Dyrskjøt
Two-year JAVELIN Solid Tumor Data Phase 1 Final Results - Andrea Apolo
Comparing Nab-Paclitaxel and Paclitaxel in Platinum-Refractory Bladder Cancer - Srikala Sridhar
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III
Guidelines for Advanced Urothelial Carcinoma in First-line Treatment for Patients Ineligible or Unfit for Cisplatin - Michiel S. Van der Heijden
Evaluating Treatments in Advanced Urothelial Carcinoma - Guru Sonpavde
Association Between Clinical Outcomes and Exploratory Biomarkers in the JAVELIN Bladder 100 Trial, Advanced Urothelial Carcinoma - Srikala Sridhar
ESMO 2020: The TROPHY-U-01 Study- Sacituzumab Govitecan for Advanced Urothelial Carcinoma - Petros Grivas
ESMO 2020: Combination Therapies in Locally Advanced or Metastatic Urothelial Carcinoma Bladder Cancer - Josh Meeks
Current Treatment Approaches in Advanced Urothelial Carcinoma - Shilpa Gupta
The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo
Prolonging Overall Survival in Patients with Muscle-Invasive Bladder Cancer - Petros Grivas
Treatment Approach: Case Study in Aggressiveness Metastatic Urothelial Carcinoma - Makarand Khochikar
Advancements in Treatments for Metastatic Urothelial Carcinoma (mUC) - Petros Grivas
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg
Assessing the Potential Cost-Effectiveness of the Addition of Atezolizumab to First-Line Platinum Chemotherapy in Advanced Urothelial Carcinoma - Ali Khaki
Progress in Bladder Cancer Research - Bishoy Faltas
IMvigor010 Primary Analysis from a Phase III Randomized Study of Adjuvant Atezolizumab versus Observation in High-Risk Muscle-Invasive Urothelial Carcinoma - Thomas Powles & Matthew Galsky
JAVELIN Bladder 100: Avelumab for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma - Thomas Powles
Controversial and Complex Cases in Urothelial Cancer - Srikala Sridhar
The Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in MIBC - Andrea Necchi
The Landscape of Advanced Bladder Cancer: A Review of the Last 30-Years - Cora Sternberg
Enfortumab Vedotin for Advanced Urothelial Carcinoma - Jonathan Rosenberg
Updates on Bladder Cancer Clinical Trials ASCO GU 2020 - Matthew Galsky
Recent Advances in the Treatment of Metastatic Urothelial Cancer - Petros Grivas
Treatments in Development for Muscle-invasive Bladder Cancer - Min Yuen Teo
Advanced Bladder Cancer Clinic: Are you Ready? - Neal Shore
Immunotherapy and Chemotherapy Use in Patients with Metastatic Bladder Cancer - Ronac Mamtani and Ravi Parikh
Circulating Tumor DNA in Urothelial Cancer - Interview with Bishoy Faltas
Upper Tract Urothelial Carcinoma Has a Luminal-Papillary T-cell Depleted Contexture and Activated FGFR3 Signaling - Bishoy Faltas
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer - Matt Galsky
Antibody Drug Conjugates for the Treatment of Metastatic Urothelial Carcinoma - Petros Grivas
Erdafitinib Treatment in Metastatic Urothelial Carcinoma - Petros Grivas
Biomarker Testing in Metastatic Urothelial Carcinoma - Petros Grivas
The Performance Status and Response to Immune Checkpoint Inhibition in Patients with Advanced Urothelial Carcinoma - Ali Khaki
Results from CALGB 90601 in Metastatic Urothelial Carcinoma - Jonathan Rosenberg
Novel New Approaches in the Neoadjuvant Disease Setting for Bladder Cancer - Petros Grivas
Urinary Diversion after Radical Cystectomy - Morgan Roupret
Assessing and Managing Toxicities with Immune Checkpoint Inhibitors - Brenda Martone
Erdafitinib in Bladder Cancer - Arjun Balar
Implications of Clinical Response Following Neoadjuvant Chemotherapy - Seth Lerner
Treating Advanced Bladder Cancer - Petros Grivas
Optimizing Treatment Outcomes in Muscle Invasive Bladder Cancer (MIBC) - Wassim Kassouf
Bladder Sparing Strategies for Urothelial Cancer - Jason Efstathiou
Neoadjuvant Treatment in Muscle Invasive Bladder Cancer- Andrea Necchi
Antibody-drug Conjugate (ADC) Sacituzumab Govitecan in Metastatic UroThelial Carcinoma - Scott Tagawa
Joshua J. Meeks on SWOG 1806 Study
Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer - Matthew Galsky
Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook - Andrea Apolo
A Conversation on Immuno-Oncology in Bladder Cancer - Petros Grivas
Update on Immunotherapy Advances in Renal and Bladder Cancer - Cora Sternberg
Advances in Bladder Cancer Beyond Immunotherapy and Checkpoint Inhibitors - Evan Yu
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials -Pedro Barata
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
The State of Advanced Bladder Cancer - New Data from AACR 2018 - Interview with Arjun Balar

Integrating (177Lu)–PSMA-617: A Practical Approach for Urology Clinics

Beyond Androgen Blockade - Exploring New Pathways for Treating mCRPC and mHSPC

AKT Inhibitors – Targeting PI3K/AKT/MTOR Signaling Axis - Cora Sternberg
Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming
Broadening Treatment Horizons with CDK4/6 Inhibitors from Breast to Prostate Cancer - Rana McKay
Bone Health Management for Advanced Prostate Cancer - Fred Saad
Tumor Heterogeneity Selective Pressure – Why We Need New Targets? - Oliver Sartor
Unlocking Precision Care: Germline & Somatic Literacy in Prostate Cancer - Elisabeth Heath
Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi
PARP Inhibitors: Targeting DNA Repair Pathways - Neal Shore
The Biological Basis of Metastatic Prostate Cancer – The Unmet Medical Need for New Targets and Novel Treatment Pathways - Dan George
The Critical Intersection of Androgen Receptor Pathways and Cell Cycle Regulation in Prostate Cancer Therapy - Rana McKay
The Current Treatment Landscape in Metastatic Hormone-Sensitive Prostate Cancer - Andrew Armstrong
PSMA PET as a Biomarker for Advanced Prostate Cancer - Oliver Sartor
2023 Key Learnings in mCRPC Treatments – Alicia Morgans
Treatment Decision Making in mHSPC: The Medical Oncologist and Patient “What the Patient Needs to Know” About this Disease and Treatment Options? - Brenda Martone
Treatment Decision Making in mCRPC: The Urologist and Patient “What the Patient Needs to Know” About His Disease and Treatment Options? - Brenda Martone
Multidisciplinary Approach in the Treatment of Metastatic Prostate Cancer - Robert Dreicer

APCCC 2024

Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman
Hypofractionation in Prostate Cancer Radiotherapy: Balancing Efficacy and Safety - Neha Vapiwala
Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin
Testosterone Recovery After ADT: Timing, Predictive Factors, and Clinical Implications - Pierre Blanchard
Radiating the Primary Tumor in Metastatic Hormone-Sensitive Prostate Cancer - Sandy Srinivas
EMBARK Trial: Enzalutamide Monotherapy and Combination Therapy for High-Risk Biochemical Recurrence - Neal Shore
Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence - Daniel Spratt
Prognostic and Predictive Factors in Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith
Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett
Sequencing Therapies in mCRPC After Progression on Combination Treatment - Ian Davis
Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis
Redefining Low-Volume Metastatic Prostate Cancer in the Era of PSMA PET Imaging - Oliver Sartor
Optimal Imaging Standards for Metastatic Castration-Sensitive Prostate Cancer - Michael Morris
The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo
Bone Health in Advanced Prostate Cancer: Findings from the STAMPEDE Trial and Hospital Episode Statistics - Noel Clarke
APCCC 2024: Bridging Clinical Gaps in Prostate Cancer Care - Silke Gillessen
Highlighting APCCC 2024: An International Prostate Cancer Meeting - Silke Gillessen & Aurelius Omlin

Latest Videos

Epigenetic Profiling Identifies Biomarkers Predicting Resistance to AR-Targeted Therapy in mCRPC - Wilbert Zwart
Advanced Prostate Cancer Treatment Cost Analysis and Patient Impact in the VA Healthcare System - Daniel Lee
Machine Learning Predicts Financial Toxicity in Stage IIA Non-Seminoma Treatments - Peter Sullivan
CheckMate 67T: Subcutaneous Nivolumab Non-Inferior to Intravenous in Advanced RCC - Laurence Albiges
Elite Female Athletes Show Higher Rates of Pelvic Floor Dysfunction and Dyspareunia - Avanti Rangnekar
36-Month Efficacy of Nadofaragene in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer - Yair Lotan
Study Finds Dose-Response Relationship Between Pack-Year Smoking and Urinary Urgency - Avanti Rangneka
BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence - Ali Nasrallah
Challenges in Transitioning Men from Active Surveillance to Watchful Waiting - Lisa Lowenstein
Belzutifan vs Everolimus Trial Data in Advanced RCC Care - Brian Rini
ARROW Study Reveals Iodine-131 PSMA Efficacy in Advanced Cancer - Evan Yu
Metformin Study Reveals Weight Management Benefits for ADT Therapy - Silke Gillessen
Addressing Cognitive Decline in Bladder Cancer Patients Through Prehab and Rehab - Sarah Psutka
Developing Radium-223: From Bone Metastases to Systemic Radiopharmaceuticals - Øyvind Bruland
Bridging Evidence to Practice: Bladder Cancer Therapy Guidelines and Global Implementation - Andrea Apolo
Study Reveals International Variations in Adherence to Prostate Cancer Quality Metrics - Adam Weiner
Lead-212 Radiopharmaceuticals Offer Promise in Targeted Cancer Treatment - Volker Wagner
Radiopharmaceutical Innovations Transforming Cancer Treatment Landscape - Jeffrey Humphrey
Primer on Inclusive Care for Sexual and Gender Minority Genitourinary Cancer Patients - Rohan Patel
Humanized Mice Reveal Role of Immune System in Prostate Cancer Therapy Efficacy - Steven Kregel
Future of Cancer Treatment: New Targets and Isotopes in Theranostics - Martin Pomper

EMBARK

EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore
Discussion Between Expert Clinicians and Patients on the EMBARK Trial, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg
EMBARK Trial: Enzalutamide Monotherapy & Combination Therapy for High-Risk Prostate Cancer - Stephen Freedland, Neal Shore, & Rana McKay
EMBARK Trial: Enzalutamide Monotherapy and Combination Therapy for High-Risk Biochemical Recurrence - Neal Shore
The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore
Advancing Prostate Cancer Care: The EMBARK Study and Implications for Clinical Practice - Stephen Freedland
Novel Hormone Therapy and Coordination of Care in High-Risk Biochemically Recurrent Prostate Cancer - Beyond the Abstract
Parsing the Evidence from the EMBARK Trial on a Promising New Drug Regimen in High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer - Matthew Cooperberg
Interpreting EMBARK Trial Results: Intensified Treatment and Hormone Therapy in High-Risk Patients - Christian Gratzke
EMBARK Trial Shows Promising Results for High-Risk Prostate Cancer Treatment, Enzalutamide's Impact on Metastasis-Free Survival - Neal Shore
The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy - Stephen Freedland

Recent Conference Coverage

  Conference Highlights Written by Physician-Scientist
South-Central Section of the American Urological Association SCS AUA 2024
View all SCS AUA 2024 coverage
2024 American Society for Radiation Oncology (ASTRO)
View all ASTRO 2024 coverage

Recent Physician-Scientist Review Articles

  State of the Evidence Review Articles
mHSPC
View all mHSPC Center of Excellence
PSMA-Targeted Therapy
View all PSMA-Targeted Therapy

Transformative Evidence

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information

EMBARK Trial

Serum tumor markers can be a blessing and a curse. After definitive local therapy for prostate cancer, prostate-specific antigen (PSA) is quite sensitive and specific, and can detect micrometastatic disease well before any radiographic or symptomatic evidence of disease. When biochemical recurrence (BCR) occurs, early detection can guide curative-intent salvage therapies such as salvage radiation.

ARASENS Trial

In the ARASENS trial (NCT02799602), darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel significantly reduced the risk of death by 32.5% (HR, 0.68; 95% CI, 0.57-0.80; P < .0001) compared with placebo plus ADT with docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC). We present efficacy and safety of darolutamide versus placebo in Black patients from ARASENS.

Trials in Progress

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information

Pivot-006 Trial

– First Patient Dosed in Expanded Access Program and Enrollment Ongoing –

Reno, Nevada (UroToday.com) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, announced that it has initiated an Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. The first patient has been dosed in the EAP and enrollment in the study is ongoing.

CLARIFY Trial


  • United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for 64Cu-SAR-bisPSMA diagnostic in prostate cancer patients with biochemical recurrence (BCR), AMPLIFY.
  • The positive results of the completed COBRA and PROPELLER trials, including the significantly higher uptake and retention in lesions compared to standard-of-care (SOC) imaging, as well as the substantial increase in the number of lesions detected with next-day imaging compared to same-day imaging, formed the data package to guide the design of the AMPLIFY trial.